Research programme: inflammatory disease-targeted antibodies - Peptimmune

Drug Profile

Research programme: inflammatory disease-targeted antibodies - Peptimmune

Alternative Names: DEEP-Ab

Latest Information Update: 29 Aug 2011

Price : $50

At a glance

  • Originator Peptimmune
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Inflammation

Most Recent Events

  • 22 Mar 2011 Suspended - Preclinical for Inflammation in USA (Parenteral)
  • 19 Jul 2010 Preclinical trials in Inflammation in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top